Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter will acquire Ohmeda anesthetic and critical care pharmaceutical product lines for $104 mil. in cash.

Executive Summary

OHMEDA PURCHASE FOR BAXTER OFFERS PAINLESS FIT: $104 MIL. CASH PURCHASE from U.K.-based BOC gives Baxter ownership of Ohmeda's anesthetic gas and critical care pharmaceutical product line that Baxter has marketed in the U.S. since 1995. Baxter said the division will be integrated into the Anesthesia Group of the company's I.V. Systems/Medical Products business.

You may also be interested in...



Baxter Adding $200 Mil. In Critical Care Rx Sales Via ESI Lederle Deal

Baxter is adding about $200 mil. in annual sales to its anesthesia/critical care line via the acquisition of ESI Lederle from Wyeth

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel